Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Genes|May 25, 2024
Immunogenetics of Systemic SclerosisOlga Gumkowska-Sroka, Kacper Kotyla, Przemysław Kotyla
Reumatologia|July 5, 2022
Adhesion molecules: a way to understand lupusKarolina Nowak, Olga Gumkowska-Sroka, Przemysław Kotyla
Genes|May 27, 2026
Immunogenetics of Idiopathic Inflammatory Myopathies: The Role of HLA Genes Within and Beyond the Ancestral HaplotypeOlga Gumkowska-Sroka, Kacper Kotyla, Przemysław Kotyla
Pharmaceuticals (Basel, Switzerland)|August 26, 2022
Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus ErythematosusPrzemysław Kotyla, Olga Gumkowska-Sroka, Bartosz Wnuk, et al.
Pharmaceuticals (Basel, Switzerland)|August 26, 2023
Novel Therapeutic Strategies in the Treatment of Systemic SclerosisOlga Gumkowska-Sroka, Kacper Kotyla, Ewa Mojs, et al.
Molecules (Basel, Switzerland)|July 15, 2026
Small-Molecule Strategies for Polymyalgia Rheumatica and Giant Cell Arteritis in Older AdultsJan Kurdybacha, Oleksii Kravets, Natalia Lekston, et al.
Current Pharmaceutical Design|May 31, 2022
Differential Impact of Biologic Therapy on Heart Function Biomarkers in Rheumatoid Arthritis Patients: Observational Study on Etanercept, Adalimumab, and TocilizumabBeata Dubiel-Braszczok, Karolina Nowak, Aleksander Owczarek, et al.
Journal of Clinical Medicine|May 11, 2019
Cytometric Characterization of Main Immunocompetent Cells in Patients with Systemic Sclerosis: Relationship with Disease Activity and Type of Immunosuppressive TreatmentOlga Gumkowska-Sroka, Krystyna Jagoda, Aleksander Owczarek, et al.
Reumatologia|December 5, 2025
Assessment of myocardial structure and function in rheumatoid arthritis patients treated with biologics: tumor necrosis factor inhibitors and anti-interleukin-6 versus conventional disease-modifying drugsBeata Dubiel-Braszczok, Olga Gumkowska-Sroka, Aleksander J Owczarek, et al.
International Journal of Molecular Sciences|May 14, 2025
The Potential of Cardiac Biomarkers in Differentiating Disease Subtypes in Patients with Systemic Sclerosis: Focus on GDF15, MR-pro ANP, and suPAROlga Gumkowska-Sroka, Anna Chudek, Aleksander Owczarek, et al.
Pageof 1